TC
SPRY icon

Tejara Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Tejara Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Buy
607,039
+396,639
+189% +$3.41M 2% 16
2026
Q1 		$1.69M Buy
+210,400
New +$2.02M 0.56% 54
2024
Q1 		– Sell
-73,739
Closed -$404K – 90
2023
Q4 		$404K Sell
73,739
-30,000
-29% -$131K 0.17% 58
2023
Q3 		$392K Sell
103,739
-29,782
-22% -$195K 0.22% 55
2023
Q2 		$895K Sell
133,521
-74,034
-36% -$494K 0.44% 47
2023
Q1 		$1.35M Buy
207,555
+172,800
+497% +$1.33M 0.69% 38
2022
Q4 		$296K Buy
+34,755
New +$226K 0.17% 80

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Tejara Capital's SPRY Position: Q2 2026 in Review

Tejara Capital increased its ARS Pharmaceuticals (SPRY) stake by 189% in Q2 2026, buying an estimated $3.41M and bringing the position to 607,039 shares worth $4.86M. The position accounts for 2% of the portfolio, ranked #16.

Tejara Capital first reported a position in SPRY in Q4 2022 and has held it in 7 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Tejara Capital held 607,039 shares of ARS Pharmaceuticals worth $4.86M as of Q2 2026.
  • Tejara Capital bought 396,639 ARS Pharmaceuticals shares in Q2 2026, an estimated $3.41M.
  • ARS Pharmaceuticals made up 2% of Tejara Capital's portfolio in Q2 2026, its #16 holding.
  • Tejara Capital first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Tejara Capital's 13F filing for Q2 2026, filed 11 Aug 2026.